Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications

Gesiane Cavalcante Nascimento; Maria José Labis da Costa; Thannuse Silva Athie; Juliana de Sales Silva; Edna Afonso Reis; Celline Cardoso Almeida-Brasil; Brian Godman; Isabella Piassi Dias Godói

doi:10.1080/15381501.2022.2029660

Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications

Gesiane Cavalcante Nascimento, Maria José Labis da Costa, Thannuse Silva Athie, Juliana de Sales Silva, Edna Afonso Reis, Celline Cardoso Almeida-Brasil, Brian Godman, Isabella Piassi Dias Godói^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The Human Immunodeficiency Virus (HIV) is considered one of the greatest public health challenges given its impact on morbidity and mortality, and there is currently no vaccine available. The costs for any vaccine have to be weighed against current preventative measures as well as its impact in reducing future infections. This was the rationale behind conducting a willingness to pay (WTP) study to guide future funding decisions. A cross-sectional study was conducted involving residents of Northern Brazil regarding their WTP for a hypothetical vaccine against HIV with 70% effectiveness. 634 individuals were interviewed and 94% accepted to use this hypothetical vaccine. The WTP was US$47.54 (200.00BRL). We believe these findings can contribute to decision-making about pricing once a HIV vaccine becomes available in Brazil and in discussions with its acceptability.

Original language	English
Pages (from-to)	145-166
Number of pages	22
Journal	Journal of HIV/AIDS and Social Services
Volume	21
Issue number	2
DOIs	https://doi.org/10.1080/15381501.2022.2029660
Publication status	Published - 2022
Externally published	Yes

Keywords

Brazil
HIV
contingent valuation
vaccine
willingness to pay

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/15381501.2022.2029660

Cite this

Nascimento, G. C., da Costa, M. J. L., Athie, T. S., Silva, J. D. S., Reis, E. A., Almeida-Brasil, C. C., Godman, B., & Godói, I. P. D. (2022). Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications. Journal of HIV/AIDS and Social Services, 21(2), 145-166. https://doi.org/10.1080/15381501.2022.2029660

@article{642a748c8e474486b2b63bba92583ea5,

title = "Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications",

abstract = "The Human Immunodeficiency Virus (HIV) is considered one of the greatest public health challenges given its impact on morbidity and mortality, and there is currently no vaccine available. The costs for any vaccine have to be weighed against current preventative measures as well as its impact in reducing future infections. This was the rationale behind conducting a willingness to pay (WTP) study to guide future funding decisions. A cross-sectional study was conducted involving residents of Northern Brazil regarding their WTP for a hypothetical vaccine against HIV with 70% effectiveness. 634 individuals were interviewed and 94% accepted to use this hypothetical vaccine. The WTP was US$47.54 (200.00BRL). We believe these findings can contribute to decision-making about pricing once a HIV vaccine becomes available in Brazil and in discussions with its acceptability.",

keywords = "Brazil, HIV, contingent valuation, vaccine, willingness to pay",

author = "Nascimento, {Gesiane Cavalcante} and {da Costa}, {Maria Jos{\'e} Labis} and Athie, {Thannuse Silva} and Silva, {Juliana de Sales} and Reis, {Edna Afonso} and Almeida-Brasil, {Celline Cardoso} and Brian Godman and God{\'o}i, {Isabella Piassi Dias}",

note = "Publisher Copyright: {\textcopyright} 2022 Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/15381501.2022.2029660",

language = "English",

volume = "21",

pages = "145--166",

journal = "Journal of HIV/AIDS and Social Services",

issn = "1538-1501",

publisher = "Routledge",

number = "2",

}

Nascimento, GC, da Costa, MJL, Athie, TS, Silva, JDS, Reis, EA, Almeida-Brasil, CC, Godman, B & Godói, IPD 2022, 'Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications', Journal of HIV/AIDS and Social Services, vol. 21, no. 2, pp. 145-166. https://doi.org/10.1080/15381501.2022.2029660

Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications. / Nascimento, Gesiane Cavalcante; da Costa, Maria José Labis; Athie, Thannuse Silva et al.
In: Journal of HIV/AIDS and Social Services, Vol. 21, No. 2, 2022, p. 145-166.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil

T2 - A cross-sectional study and the implications

AU - Nascimento, Gesiane Cavalcante

AU - da Costa, Maria José Labis

AU - Athie, Thannuse Silva

AU - Silva, Juliana de Sales

AU - Reis, Edna Afonso

AU - Almeida-Brasil, Celline Cardoso

AU - Godman, Brian

AU - Godói, Isabella Piassi Dias

PY - 2022

Y1 - 2022

N2 - The Human Immunodeficiency Virus (HIV) is considered one of the greatest public health challenges given its impact on morbidity and mortality, and there is currently no vaccine available. The costs for any vaccine have to be weighed against current preventative measures as well as its impact in reducing future infections. This was the rationale behind conducting a willingness to pay (WTP) study to guide future funding decisions. A cross-sectional study was conducted involving residents of Northern Brazil regarding their WTP for a hypothetical vaccine against HIV with 70% effectiveness. 634 individuals were interviewed and 94% accepted to use this hypothetical vaccine. The WTP was US$47.54 (200.00BRL). We believe these findings can contribute to decision-making about pricing once a HIV vaccine becomes available in Brazil and in discussions with its acceptability.

AB - The Human Immunodeficiency Virus (HIV) is considered one of the greatest public health challenges given its impact on morbidity and mortality, and there is currently no vaccine available. The costs for any vaccine have to be weighed against current preventative measures as well as its impact in reducing future infections. This was the rationale behind conducting a willingness to pay (WTP) study to guide future funding decisions. A cross-sectional study was conducted involving residents of Northern Brazil regarding their WTP for a hypothetical vaccine against HIV with 70% effectiveness. 634 individuals were interviewed and 94% accepted to use this hypothetical vaccine. The WTP was US$47.54 (200.00BRL). We believe these findings can contribute to decision-making about pricing once a HIV vaccine becomes available in Brazil and in discussions with its acceptability.

KW - Brazil

KW - HIV

KW - contingent valuation

KW - vaccine

KW - willingness to pay

UR - http://www.scopus.com/inward/record.url?scp=85124344395&partnerID=8YFLogxK

U2 - 10.1080/15381501.2022.2029660

DO - 10.1080/15381501.2022.2029660

M3 - Article

AN - SCOPUS:85124344395

SN - 1538-1501

VL - 21

SP - 145

EP - 166

JO - Journal of HIV/AIDS and Social Services

JF - Journal of HIV/AIDS and Social Services

IS - 2

ER -

Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this